
Getting a testosterone test and getting a meaningful testosterone test are not the same thing. The time of day the sample is drawn, what the panel includes beyond total T, how many separate draws are required for a valid diagnosis, how the results are read against both symptoms and the wider hormonal picture: each of these factors determines whether the evaluation produces a real clinical answer or just a number.
Most men get the number. Fewer get the answer.
For men in Ontario looking for an evaluation structured around the complete picture, TRT Toronto programs begin with a full fasting morning hormone panel, including free testosterone, LH, and FSH alongside total T, before any clinical conclusions are drawn.
Why the Source of Low Testosterone Changes Everything
Primary hypogonadism means the testes themselves are underproducing testosterone despite receiving correct signalling from the brain. Because the hypothalamic-pituitary axis detects low testosterone in the bloodstream, it responds by increasing gonadotropin output. LH and FSH climb in an attempt to stimulate the testes harder. The testes cannot respond adequately, whether due to injury, genetic factors, chemotherapy, or chronic illness. The result is low testosterone paired with elevated LH and FSH.
Secondary hypogonadism runs in the opposite direction. The testes retain the capacity to produce testosterone but are not receiving adequate instruction from above. The pituitary is not secreting sufficient LH, so the testes never receive the signal to ramp up production. Low testosterone appears alongside low or inappropriately normal LH and FSH. The manufacturing capacity exists; the order never arrives.
The clinical relevance is direct. A man with primary hypogonadism needs exogenous testosterone because his testes cannot produce it regardless of stimulation. A man with secondary hypogonadism may have treatment options that work further up the hormonal signalling chain. Both present with overlapping symptoms. The extended blood panel differentiates them.
What a Complete Diagnostic Panel Requires
A total testosterone level drawn at the wrong time of day, on a single occasion, is an incomplete test. Testosterone follows a circadian rhythm, peaking between 7 and 10 a.m. and declining through the afternoon. The difference between morning peak and afternoon trough can reach 20 to 30 percent of total concentration. A genuinely deficient man tested mid-afternoon can produce a reading inside the standard reference range. The draw looks normal. The deficiency persists.
The Endocrine Society’s 2018 Clinical Practice Guideline on testosterone therapy specifies that confirming hypogonadism requires both matching symptoms and consistently low testosterone on at least two separate fasting morning blood draws. One result is not a diagnosis.
A complete panel extends beyond total testosterone. Free testosterone captures the biologically active fraction not bound to sex hormone-binding globulin (SHBG). SHBG rises with age, and men with elevated binding protein levels may carry total testosterone in the low-normal range while their free testosterone, the fraction cells can actually uptake and use, is functionally deficient. Total T looks borderline; free T tells the real story.
LH and FSH are measured to reveal whether the pituitary is signalling correctly and whether the testes are responding. SHBG itself contextualizes the total testosterone result and determines whether free testosterone measurement is clinically necessary. Together, these markers transform a single number into an actual clinical picture.
A total testosterone reading below approximately 300 ng/dL on two fasting morning draws, corroborated by symptoms and supported by the extended panel, meets the Endocrine Society’s diagnostic standard.

What Testosterone Governs Physiologically
Testosterone’s biological reach extends considerably beyond the functions most men associate with it. Through its stimulation of erythropoietin synthesis in the kidneys, it regulates red blood cell production. When testosterone falls, erythropoietin output declines, circulating red blood cells decrease, and tissue oxygen delivery drops during both rest and exertion. This is the physiological mechanism behind the disproportionate fatigue that characterizes low T: not vague tiredness, but a measurable reduction in the blood’s capacity to deliver oxygen to working tissue.
It acts on dopamine pathways in the prefrontal cortex as well, which is why deficiency tends to surface first as motivational blunting, emotional flatness, and cognitive slowness rather than the more recognizable presentation of sexual dysfunction. Bone mineral density, lean muscle maintenance, fat distribution, and insulin sensitivity are each under its influence. The symptom profile is broad precisely because the hormone’s reach is broad, and because it intersects with systems that have their own presenting complaints.
Modern Treatment Options
When a clinical diagnosis of hypogonadism is confirmed, testosterone replacement therapy is the established medical intervention. The treatment objective is mid-normal range serum testosterone, sufficient to relieve symptoms without the risks associated with supraphysiological concentrations.
Three delivery formulations account for most clinical prescribing.
Intramuscular Injections
Testosterone cypionate or enanthate, administered weekly or bi-weekly by intramuscular injection, offers reliable absorption and straightforward dose titration. The pharmacokinetic pattern involves a peak in the days following each injection and a gradual trough before the next. Men with greater sensitivity to hormonal fluctuation may find this rhythm perceptible in energy or mood toward the end of each cycle. It remains the most widely prescribed formulation.
Transdermal Gels
Daily testosterone gels applied to the shoulders or upper arms produce more stable serum concentrations than injection cycles. The practical consideration is skin-to-skin transfer: gel that has not fully absorbed can be passed to a partner or child through direct contact, making application timing and site selection relevant. For men who prioritize hormonal consistency, gels are a common clinical alternative.
Subcutaneous Pellets
Testosterone pellets are implanted beneath the skin in a brief in-office procedure and release hormone gradually over three to six months. They provide the most stable hormonal profile of the three formulations, requiring no weekly or daily administration. Mid-cycle dose adjustments are not possible without a new procedure, which is the primary clinical trade-off.
Monitoring and Known Risks
TRT is a supervised medical treatment with structured follow-up requirements. Per Endocrine Society guidelines, serum testosterone and hematocrit are measured six to twelve weeks after initiation. Testosterone stimulates erythropoietin-driven red blood cell production, and hematocrit above approximately 54 percent increases blood viscosity significantly, carrying cardiovascular risk. Dose adjustment or temporary interruption corrects this in most cases, but detection requires consistent testing.
PSA is evaluated during the first year of treatment. Fertility warrants a separate conversation before starting: TRT suppresses sperm production in most men by reducing LH-driven testicular stimulation. Men who want biological children should raise this before beginning treatment, as alternative protocols can address testosterone deficiency while preserving fertility. Once levels stabilize, follow-up testing continues every three to six months.
The Diagnosis Shapes the Treatment
The number on a testosterone result is a starting point, not a conclusion. Whether the deficiency originates in the testes or in the signalling chain above them, whether free testosterone tells a different story than total T, whether morning timing was respected on the draw: these details shape what the diagnosis actually means and which treatment path makes sense. Getting them right at the outset determines the quality of everything that follows.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree